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found to be unprepared to deal with this new, unknown disease.
Despite the reaction of the scientific world is planetary with more than
2000 trials started in a few months, so far there are neither specific
treatments nor vaccines. The virus and its effects remain unknown and
shrouded in mystery. There is not a clear enemy to combat such as a
coronary plaque or a leaking or stenotic valve (Figure 1).
Psychologically, the unknown generates fear and anxiety. It follows
that perception of the COVID-19 pandemic is worse than that of
CVD although the consequences and the number of victims between
the 2 are incomparable.
The COVID-19 outbreak, often concentrated in limited areas, has
rapidly transformed individual undertakings to a mass scenario which is
communicated daily in numbers of infected or deaths on television and
social media with the result that everybody has lost sight, significance,
and importance of every single death within an epidemiological forest
of numbers. In front of this, the medical-scientific world remains
stunned. It implodes, with a lack of ideas on how to react. The defence
strategy consists of hiding and shutting down society, despite the
knowledge that this cannot last, and the price might be even higher
than the disasters caused by the virus which, in any case, are signifi-
cantly less than those of other epidemics, as the one of CVD.
However, CVD does not reach the interest of the media. We are sim-
ply used to it.
Two epidemics at the same time
are too much: the collateral
damage
Emphasis on COVID-19 has created concerns about contracting the
infection during a hospital stay, ultimately causing a series of collateral
damages.4 This is true for all diseases, but particularly so for CVD and
more specifically, for acute coronary syndromes (ACS), a time-
dependent pathology.
All over Europe and the USA, during the early days of the epidemic,
fewer patients reached the hospitals for ACS and. . .ACS were not
prevented by the coronavirus, despite the proposal that the lockdown
had results in less stress and therefore, less ACS or infarcts. This is not
true, actually, the opposite may be true: less exercise, fewer labora-
tory, or other tests and probably more weight gain is likely to increase
rather than decrease ACS during a lockdown.
But, more than anything else, the anxiety generated by the unknown
and the fear of acquiring SARS-COV-2 infections in the hospitals has
prevented patients from seeking effective medical interventions,
compromising CV care. The results are more sudden cardiac death,
more complications of acute myocardial infarction (often experienced at
home), more heart failure, and, eventually, more deaths.5,6 Therefore,
actually, the COVID-19 outbreak has negatively affected CVD by shift-
ing the attention of patients like Mr Brown from his coronary problems
to those related to the new coronary virus. Sorry corona not coronary
virus! This is where the confusion lies.
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Insights From the National Society of Cardiology Journals
Introduction
Most studies on heart failure (HF) management published in 2019 by
high-ranking impact factor international journals focus on drug therapy.
This included administration of sacubitril-valsartan with initiation dur-
ing the index admission and the benefits of SGLT2 inhibitors in reduc-
ing cardiovascular mortality and HF. Most of these studies, targeting a
broad readership, fail to characterize important local issues.
Prof. Claudio Rapezzi
Centro Cardiologico Universitario di Ferrara, 
University of Ferrara, Ferrara, Italy. 
Maria Cecilia Hospital, Cotignola (RA), Italy
Roberto Ferrari MD
Corresponding author
Chair of Cardiology, Azienda
Ospedaliero-Universitaria di Ferrara, 
Ospedale di Cona, Via Aldo Moro 8, 
44124 (Cona),Ferrara, Italy. 
Centro Cardiologico Universitario di Ferrara, 
Maria Cecilia Hospital, Cotignola (RA), Italy  
Email: fri@unife.it 
Telephone: +39 0532 239882
Dr Paolo Cimaglia. 








/eurheartj/article/42/6/557/5986679 by 81728827 user on 11 August 2021
Improvement in HF management needs to take into account specific-
ities from different European Society of Cardiology (ESC) member
countries. This approach may be achieved and disseminated to cardiol-
ogists by the National Society of Cardiology Journals (NSCJ). During
the ESC Congress 2019, the ESC Editors’ Network started an initiative
intended to boost dissemination of cardiology research published in
the NSCJ by summarizing in a review paper the evidence gathered in
selected areas. The ESC Editors Network members decided the first
topic of such a review to be publications in the field of HF.
Epidemiology
Inequalities in the prevalence of risk factors, cardiovascular disease
burden, cardiovascular mortality, and implementation of some thera-
peutic methods (coronary interventions, device implantations, and car-
diac surgery) among the ESC member countries have recently been
shown in the ATLAS study. These shortcomings depend on socio-
economic factors and affect more predominantly middle-income than
high-income countries. In a single-centre observational study of 1006
patients admitted to a coronary care unit in Egypt, Badran et al.1 esti-
mated the prevalence of HF by gender and preserved or reduced left
ventricular ejection fraction (LVEF). They reported a higher prevalence
of HF and a higher incidence of HF with reduced ejection fraction
(HFrEF) among women. Female patients were older, more likely to be
obese, with more co-morbidities, had less acute coronary syndromes
and required fewer coronary interventions, but had a prognosis similar
to men.
Nationwide information on mortality and readmissions in HF
patients is also of interest. A retrospective analysis from Spain aimed
to identify factors associated with in-hospital mortality and readmis-
sions in 77 652 HF patients.2 In-hospital mortality was 9.2%, rising to
14.5% at 1 year. The 1-year cardiovascular readmission rate was 33%.
Risk factors associated with mortality were stroke, metastatic cancer,
cardiorespiratory failure, shock, and acute myocardial infarction. Risk-
standardized mortality rates were lower among patients discharged
from high-volume hospitals. Importantly, the availability of a cardiology
department at the hospital was associated with better outcomes.
Specific causes of heart failure
Calcific aortic valve disease (CAVD) is a common disorder which may
progress while remaining clinically unrecognized. However, the pro-
gression mechanisms remain unknown. In a single-centre study from
Bulgaria, Tomova et al.3 tested the hypothesis that the polymorphism
rs10455872 at the lipoprotein (a) (LPa) gene locus increases the risk of
CAVD. In a comparison of 108 CAVD patients with 38 controls, they
reported that the presence of1 mutant allele of the gene was associ-
ated with a four-fold greater risk for CAVD. A report from the
Austrian Journal of Cardiology by Kauffmann et al.4 demonstrated that the
diagnosis of transthyretin-amyloidosis has recently improved signifi-
cantly with structural screening by magnetic resonance imaging (MRI).
The coexistence of CAVD and transthyretin-amyloidosis has substan-
tial implications. The study suggested the value of the electrocardio-
gram, echocardiography, MRI, technetium radionuclide imaging, and
endomyocardial biopsy in these patients.4 Subclinical myocardial in-
volvement is common in systemic sclerosis (SSc) and is associated with
HF and a worse prognosis. In a study of 73 SSc patients from Hungary,
Vertes et al.5 tested the 2D-speckle-tracking-derived global longitudi-
nal strain (GLS) for the detection of early myocardial involvement.
Lower GLS values were found in patients compared with gender- and
age-matched healthy controls. GLS values correlated with the duration
of the disease from the onset of Raynaud’s phenomenon, from the first
non-Raynaud symptoms, and with the New York Heart Association
(NYHA) functional class.
Pathogenesis
In a prospective Russian study including 297 patients, Lelyavina et al.6
reported the potential for differentiation, regeneration, and growth of
satellite skeletal muscle precursor cells obtained from patients with
HFrEF. The studied parameters were similar to those found in healthy
donors. This may explain why walking >1.5 h/day induces more physi-
ological reverse myocardial remodelling than aerobic training.
Diagnosis
In another Russian study, Vdovenko et al.7 compared 80 patients
(NYHA Class I–IIa) with chronic HFpEF with 30 healthy controls by us-
ing the 6-minute walk-test and echocardiography. All patients had dia-
stolic dysfunction (60 abnormal relaxation patterns and 20 pseudo
normal patterns) with reduced global and segmental LV strain. The im-
pact of HF on other body organs has been analysed by Içen et al.8 from
Turkey assessing liver stiffness (LS) in HF patients. Liver stiffness esti-
mated using an ElastPQ technique was increased in patients with more
advanced NYHA class. A higher LS was associated with higher right
ventricular myocardial performance index, regurgitation pressure gra-
dient, NT-proBNP, and aspartate aminotransferase levels. Assuming
that the SYNTAX score is not just a measure of the severity but also
the complexity of coronary artery disease €Oztürk et al.9 analysed the
degree of coronary atherosclerosis, estimated by SYNTAX score and
myocardial viability in Turkish patients with ischaemic cardiomyopathy.
Patients without viability had a significantly higher SYNTAX score
compared with those with viable myocardium.
Treatment
Clinical implications of HF associated with valvular heart disease has
been reported by several NSCJ. Transcatheter aortic valve implanta-
tion (TAVI) is an alternative to surgical aortic replacement for symp-
tomatic severe aortic stenosis. Indications are now rapidly expanding
towards patients at lower surgical risk. Generalization of the transfe-
moral vascular approach, technological advances, and increased opera-
tor skills have resulted in higher rates of procedural success and
improved long-term survival. However, data on the incidence of read-
mission for HF after successful TAVI are scarce.
A French study on 1139 patients, by Guedeney et al.10 reported that
readmission for HF occurs in 1/10 patients after TAVI and suggests a
strong risk factor for mortality. The main risk factors for HF readmis-
sion were LVEF 35%, chronic pulmonary disease, chronic kidney dis-
ease, diabetes, and atrial fibrillation. Along with international
multicentre trials on the percutaneous mitral repair of functional mitral
regurgitation associated with HF, national registries provide valuable
real-life results in unselected patients which may inform clinical deci-
sion making at a local level.
Benak et al. reported a cohort of 30 MitraClip implantations in
Czech patients with dilated cardiomyopathy and severe functional mi-
tral regurgitation. Procedural success was 97% with no 90-day mortal-
ity. At 1 year, significant improvements in functional class, and quality
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myocardial mass, an increase in systolic and diastolic arterial pressure
and a mortality rate of 10%.
Conclusion
Instead of publications in high-ranking impact factor international jour-
nals, NSCJ cover a wide spectrum of diagnostic and therapeutic modali-
ties taking into account the national specifics of HF. In contrast, studies
published in NSCJ are often single-centre and observational. However,
information on HF strategies at a national level are useful in implement-
ing ESC clinical practice guidelines and in optimizing HF patients’ care.
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The right ventricle in COVID-19 patients
A forgotten essential chamber that may be involved in the cardiac complications
of COVID-19
The right ventricle seems to have been forgotten among heart cham-
bers, although some studies have shown its crucial role in coronavirus
disease 2019 (COVID-19). Interestingly, both its size and function are
believed to be associated with cardiac complications and mortality in
COVID-19.
COVID-19 is caused by severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) which spread globally after the first case was ob-
served in Wuhan at the end of 2019.1 Recent studies suggested that
COVID-19 may be accompanied by cardiac complications, including
acute coronary syndrome, cardiac arrhythmia, myocarditis, pericardi-
tis, and heart failure in nearly 20% of patients, which are ssociated with
an increased risk of mortality.2 Laboratory data such as cardiac tropo-
nin as well as echocardiography parameters can be effective means of
cardiac assessment in these patients. Transthoracic echocardiography
(TTE) is the optimum method of cardiac imaging used in COVID-19
patients which is able to diagnose different cardiac abnormalities
including haemodynamic dysfunction. Also, it is useful for the predic-
tion of future cardiac morbidity in these patients.3
Reduced right ventricular (RV) activity is a good predictor for heart
failure and cardiac mortality.4 The effect of COVID-19 on the right
ventricle activity is in the main unknown. It seems that the pathophysi-
ological pathways of COVID-19 including increased afterload after
acute respiratory distress syndrome, pulmonary embolism, cytokine-
negative inotropic effects, and renin–angiotensin system dysfunction
are possible mechanisms for RV dysfunction in COVID-19 patients.5 A
summary of some studies which have been conducted to assess RV
function in COVID-19 patients is presented in Table 1.
Li et al. performed an echocardiographic investigation in 120 cases
of COVID-19. They assessed RV fractional area change, tricuspid annu-
lar plane systolic excursion, and Doppler tricuspid tissue annular veloc-
ity. In their study, RV function was categorized by right ventricular
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